Let the price negotiations begin, the top executive for the U.K. price watchdog suggested today after the agency nixed Roche's pioneering breast cancer drug Kadcyla as too expensive.
written on 23.04.2014
NICE rejects Roche's hot new breast cancer drug Kadcyla, then invites negotiations
